Dr. Brian Miller

Dr. Brian Miller, M.D., M.B.A., M.P.H., FACPM is a practicing hospitalist, Associate Professor of Medicine and Business (courtesy) at the Johns Hopkins University, and a Nonresident Fellow at the American Enterprise Institute. He splits his time between the practice of hospital medicine and interdisciplinary health policy research focused on payment policy, FDA regulatory policy, and healthcare competition policy. Dr. Miller previously served as a Medical Officer in the Office of New Drugs at the Center for Drug Evaluation and Research at the U.S. Food and Drug Administration, where he focused on pre- and post-market safety regulation, including the review and approval of valbenazine, a first-in-class breakthrough new molecular entity. He also served as a Senior Policy Fellow for Health IT at the Federal Communications Commission, in addition to serving as a Special Advisor in the Federal Trade Commission's Office of Policy Planning. At the FTC, he worked on competition policy and served as an in-house physician expert for the Bureau of Competition, assisting in merger review and enforcement in health systems, pharmaceuticals, and retail drug stores, including the FTC's successful action blocking the $7 billion Advocate - NorthShore merger. Prior to the FTC, Dr. Miller was a Fellow at the Centers for Medicare & Medicaid Innovation, where he co-managed the ACO Investment Model, a $114 million project focused on ACOs in rural areas. Dr. Miller previously served as a member of the Medicare Evidence Development & Coverage Advisory Committee and a consulting expert witness at the FTC. Dr. Miller is currently serves as a Commissioner on the Medicare Payment Advisory Commission, which advises Congress on the $800 billion Medicare program, and as a member of the Board of Trustees of the North Carolina State Health Plan, a $4.5 billion/year organization providing health benefits for >700,000 state employees, dependents, and retirees.

Dr. Miller is board certified in American Board Of Internal Medicine and American Board Of Preventive Medicine. He is actively involved in clinical research, co-authoring 48 peer reviewed articles.